Publicaciones en colaboración con investigadores/as de University of Parma (28)

2024

  1. AI is a viable alternative to high throughput screening: a 318-target study

    Scientific Reports, Vol. 14, Núm. 1

  2. Age-Related Differences in the Presentation, Management, and Clinical Outcomes of 100,000 Patients With Venous Thromboembolism in the RIETE Registry

    Archivos de Bronconeumologia, Vol. 60, Núm. 3, pp. 143-152

  3. Correction to: AI is a viable alternative to high throughput screening: a 318-target study (Scientific Reports, (2024), 14, 1, (7526), 10.1038/s41598-024-54655-z)

    Scientific Reports

  4. Impact of Liver Cirrhosis, Severity of Cirrhosis, and Portal Hypertension on the Difficulty and Outcomes of Laparoscopic and Robotic Major Liver Resections for Primary Liver Malignancies

    Annals of Surgical Oncology, Vol. 31, Núm. 1, pp. 97-114

  5. Impact of liver cirrhosis, severity of cirrhosis and portal hypertension on the difficulty of laparoscopic and robotic minor liver resections for primary liver malignancies in the anterolateral segments

    European Journal of Surgical Oncology, Vol. 50, Núm. 1

  6. Impact of neoadjuvant chemotherapy on short-term outcomes after simple and complex minimally invasive minor hepatectomy for colorectal liver metastases: A propensity-score matched and coarsened exact matched study

    European Journal of Surgical Oncology, Vol. 50, Núm. 6

  7. Propensity Score-Matching Analysis Comparing Robotic Versus Laparoscopic Limited Liver Resections of the Posterosuperior Segments: An International Multicenter Study

    Annals of surgery, Vol. 279, Núm. 2, pp. 297-305

  8. Propensity score-matched analysis comparing robotic versus laparoscopic minor liver resections of the anterolateral segments: an international multi-center study of 10,517 cases

    Annals of Surgery

  9. Targeting DNA2 overcomes metabolic reprogramming in multiple myeloma

    Nature Communications, Vol. 15, Núm. 1

  10. Treatment and outcomes in breast cancer patients: A cross section study from the EUSOMA breast centre network

    European Journal of Cancer, Vol. 196

2023

  1. Impact of body mass index on perioperative outcomes of laparoscopic major hepatectomies

    Surgery (United States), Vol. 174, Núm. 2, pp. 259-267

  2. Impact of body mass index on the difficulty and outcomes of laparoscopic left lateral sectionectomy

    European Journal of Surgical Oncology, Vol. 49, Núm. 8, pp. 1466-1473

  3. Impact of liver cirrhosis and portal hypertension on minimally invasive limited liver resection for primary liver malignancies in the posterosuperior segments: An international multicenter study

    European Journal of Surgical Oncology, Vol. 49, Núm. 10

  4. Impact of liver cirrhosis, the severity of cirrhosis, and portal hypertension on the outcomes of minimally invasive left lateral sectionectomies for primary liver malignancies

    Surgery (United States), Vol. 174, Núm. 3, pp. 581-592

  5. Impact of neoadjuvant chemotherapy on the difficulty and outcomes of laparoscopic and robotic major liver resections for colorectal liver metastases: A propensity-score and coarsened exact-matched controlled study

    European Journal of Surgical Oncology, Vol. 49, Núm. 7, pp. 1209-1216

  6. Propensity-score Matched and Coarsened-exact Matched Analysis Comparing Robotic and Laparoscopic Major Hepatectomies: An International Multicenter Study of 4822 Cases

    Annals of Surgery, Vol. 278, Núm. 6, pp. 969-975

2022

  1. Author Correction: Stem cell architecture drives myelodysplastic syndrome progression and predicts response to venetoclax-based therapy (Nature Medicine, (2022), 28, 3, (557-567), 10.1038/s41591-022-01696-4)

    Nature Medicine

  2. Stem cell architecture drives myelodysplastic syndrome progression and predicts response to venetoclax-based therapy

    Nature Medicine, Vol. 28, Núm. 3, pp. 557-567

  3. The impact of the SARS-COV-2 pandemic on the quality of breast cancer care in EUSOMA-certified breast centres

    European Journal of Cancer, Vol. 177, pp. 72-79

  4. Venous Thrombosis within 30 Days after Vaccination against SARS-CoV-2 in a Multinational Venous Thromboembolism Registry

    Viruses, Vol. 14, Núm. 2